Showing 829 results
-
Media Release /- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014- Secukinumab is the first selective…
-
Media Release /Through music and resources Our Voice in Song™ inspires people living with relapsing MS to become more active managers of their diseaseInitiative launches with nationwide release of "I Can Do This,"…
-
Media Release /- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1]- Additionally, sustained remissions were achieved up…
-
Media Release /- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus…
-
Media Release /- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies-…
-
Media Release /- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis- Offering a new treatment option for patients,…
-
Media Release /Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1)Signifor LAR, a next-generation somatostatin analog, provides a new option…
-
Media Release /- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment- After two…
-
Media Release /- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16- In…
-
Media Release /- EXPEDITION trial results demonstrated QVA149 (indacaterol/glycopyrronium) met all primary and secondary endpoints(1),(2),(3),(4)- Treatment with QVA149 for 12 weeks provided robust dual…
